Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease
Journal of Neuroendocrinology · 2026-07 · 38 (7)
DOI: 10.1111/jne.70226 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 30.06.2026. Verfasst von Markus Ammann und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoid Heart Disease, Hepatectomy, Neuroendocrine Tumors. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Carcinoid heart disease (CHD) is associated with advanced neuroendocrine tumor liver metastases (NETLM) and may preclude surgical cytoreduction. We assessed perioperative and long‐term outcomes of hepatectomy in patients with CHD. We retrospectively analyzed 311 patients undergoing cytoreductive hepatectomy for intestinal NETLM: non‐functional ( n = 163), carcinoid syndrome (CS) without CHD ( n = 110), and CHD ( n = 38), including patients undergoing pre‐hepatectomy valve replacement. CHD patients more frequently had >10 liver metastases (78%) and larger lesions (median 9.5 cm) and required major hepatectomy more often (58%). Major morbidity was higher in CHD (up to 47%), yet 90‐day mortality remained low (≤4%). Median overall survival after hepatectomy was comparable across groups (12.5 vs. 9.1 vs. 11.4 years; p = .19), including matched analyses. With optimal cardiac management, cytoreductive hepatectomy in CHD is feasible and provides long‐term survival comparable to patients without CHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Surgery, State Hospital Wiener Neustadt, Wiener Neustadt, Austria.
- Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria.
- Department of Surgery, HPB Center, Vienna Health Network, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Jonas Santol, Yawen Dong, Thorvardur R Halfdanarson
Zitieren
APA
Ammann, M., Gudmundsdottir, H., Podrascanin, V., Santol, J., Pereyra, D., Dong, Y., Connolly, H. M., Pellikka, P. A., Schaff, H. V., Crestanello, J. A., Thiels, C. A., Warner, S. G., Truty, M. J., Kendrick, M. L., Smoot, R. L., Halfdanarson, T. R., Nagorney, D. M., & Starlinger, P. P. (2026). Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease. Journal of Neuroendocrinology, 38(7). https://doi.org/10.1111/jne.70226
Vancouver
Ammann M, Gudmundsdottir H, Podrascanin V, Santol J, Pereyra D, Dong Y, et al. Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease. Journal of Neuroendocrinology. 2026;38(7). doi:10.1111/jne.70226
BibTeX
@article{Ammann2026,
author = {Ammann, Markus and Gudmundsdottir, Hallbera and Podrascanin, Vanja and Santol, Jonas and Pereyra, David and Dong, Yawen and Connolly, Heidi M and Pellikka, Patricia A and Schaff, Hartzell V and Crestanello, Juan A and Thiels, Cornelius A and Warner, Susanne G and Truty, Mark J and Kendrick, Michael L and Smoot, Rory L and Halfdanarson, Thorvardur R and Nagorney, David M and Starlinger, Patrick P},
title = {Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart disease},
journal = {Journal of Neuroendocrinology},
year = {2026},
volume = {38},
number = {7},
doi = {10.1111/jne.70226}
}
EUVIMED